Practical Treatment with Minimum Maintenance Dose of Anti-Thyroid Drugs for Prediction of Remission in Graves' Disease
| Autor: | Yukiko Izumi, Keiko Takeoka, Taku Kashiwai, Nobuyuki Amino, Ke-ita Tatsumi, Yuki Shimaoka, Toru Takano, Hisato Tada, Yoh Hidaka |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Adult
Male endocrine system medicine.medical_specialty endocrine system diseases Endocrinology Diabetes and Metabolism Graves' disease Gastroenterology Endocrinology Pharmacotherapy Antithyroid Agents Maintenance therapy Predictive Value of Tests Recurrence Internal medicine Humans Medicine Euthyroid Prospective Studies Methimazole business.industry Maintenance dose Remission Induction Thyroid Middle Aged medicine.disease Graves Disease Discontinuation medicine.anatomical_structure Propylthiouracil Female business hormones hormone substitutes and hormone antagonists medicine.drug |
| Zdroj: | Endocrine Journal. 50:45-49 |
| ISSN: | 1348-4540 0918-8959 |
| Popis: | Although many researchers have reported clinical and laboratory parameters for prediction of remission in Graves' disease during or after anti-thyroid drug therapy, there is no reliable one to assure the complete remission. We prospectively examined a practical therapy with minimum maintenance dose of anti-thyroid drugs for prediction of remission in Graves' disease. Fifty-seven patients with Graves' disease were treated with anti-thyroid drugs at the initial dose of 30 mg/day of methimazole (MMI) or 300 mg/day of propylthiouracil (PTU). Then, doses were gradually decreased, and finally discontinued when the patients were able to maintain euthyroid (normal FT4 and TSH) for at least 6 months with the minimum maintenance dose (MMI 5 mg every other day or PTU 50 mg every other day). After discontinuation of drugs, FT4, FT3, TSH and TSH-binding inhibitory immunoglobulin (TBII) were measured every one to two months for the first 6 months and every 3-4 months for the next 18 months to confirm continuous remission. After 2 years of drug cessation, 46 (81%) of 57 patients were in remission and the other 11 patients had relapsed into thyrotoxicosis. At the time of drug discontinuation, the serum concentration of FT4, FT3 and TSH, titers of anti-thyroglobulin antibodies and anti-thyroid microsomal antibodies, goiter size were not different between the remission and relapse groups. At the time of drug cessation, the activities of TBII and thyroid-stimulating antibodies (TSAb) overlapped between the two groups, although they were significantly lower in the remission group than in the relapse group (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|